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Abstract
Traumatic brain injury (TBI) is an important public health problem, comparable to stroke in incidence and prevalence. Few
interventions have proven efficacy in TBI, and clinical trials are, therefore, necessary to advance management in TBI. We
describe the current clinical trial landscape in traumatic brain injury and compare it with the trial efforts for stroke. For this,
we analysed all stroke and TBI studies registered on the US Clinical Trials (www.clinicaltrials.gov) database over a 10-year
period (01/01/2000 to 01/31/2013). This methodology has been previously used to analyse clinical trial efforts in other
specialties. We describe the research profile in each area: total number of studies, total number of participants and change
in number of research studies over time. We also analysed key study characteristics, such as enrolment number and scope of
recruitment. We found a mismatch between relative public health burden and relative research effort in each disease.
Despite TBI having comparable prevalence and higher incidence than stroke, it has around one fifth of the number of
clinical trials and participant recruitment. Both stroke and TBI have experienced an increase in the number of studies over
the examined time period, but the rate of growth for TBI is one third that for stroke. Small-scale (,1000 participants per
trial) and single centre studies form the majority of clinical trials in both stroke and TBI, with TBI having significantly fewer
studies with international recruitment. We discuss the consequences of these findings and how the situation might be
improved. A sustained research effort, entailing increased international collaboration and rethinking the methodology of
running clinical trials, is required in order to improve outcomes after traumatic brain injury.
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Introduction
Traumatic Brain Injury (TBI) and stroke both have major public
health impacts. They are common causes of brain injury, which
present acutely and result in long-term personal and social
consequences. Both change lives in an instant. Together, they
account for 51% of mortality from central nervous system disease
[1,2]. The US prevalence for stroke and TBI are 6.8 million and 5.3
million, and the annual incidence are 800 000 and 1.6 million for
stroke and TBI respectively [3–6]. Both conditions, but TBI in
particular, are associated with a wide range of physical, cognitive
and psychological deficits, which persist for years after injury [7–
13]. Importantly, the age of onset in TBI and stroke is different. Half
of all TBI events occur in people of working age (20–65 years old),
which results in a longer burden of disability [3]. The cognitive and
psychological deficits are also particularly detrimental in this age
group because of the associated negative impact on return to
previous educational or employment status [11–17]. Additionally,
behavioural and psychiatric sequelae after TBI can have major and
long-lasting disruptive effects on family relationships, with family
members reporting high levels of psychological distress and
cessation of work to provide care [18–21]. TBI consequently has
a significant financial public health burden. Health economic
estimates suggest that TBI accounts for over $70 billion (range $48–
72 billion) in direct (e.g. long-term burden of medical care) and
indirect (e.g. loss of productivity in a working population) costs in the
USA annually [4,22,23], which is comparable to the estimated
annual costs of stroke (range $38–74 billion) [24,25].
These similarities between stroke and TBI in public health
relevance are not reflected in evidence based treatment options or
clinical trial efforts. Stroke translational research, with evidence
from large-scale clinical trials, has resulted in changes in practice
and improvements in outcome. The recent ‘FAST’ public health
campaign in the UK has used billboard posters and TV adverts to
promote rapid recognition of stroke by family members [26], thus
enabling patients to reach hospital more quickly. The importance
of timing in stroke treatment is driven by the tight timeframe
required for thrombolysis, which has proven to be one of the most
effective acute stroke treatment in recent years [6,27–32].Thus,
clinical research influences clinical practice, patient outcomes and
government policy. On the other hand, the management of TBI
remains based on mostly Level 2 and 3 evidence [33], with many
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putative neuroprotective strategies failing to realise their potential
when translated from animal into human studies [34]. For
instance, while therapeutic hypothermia showed promise in
animal models, early human studies did not find conclusive
evidence of benefit in TBI [35–37]. However, this intervention is
currently the subject of a large multi-centre RCT, which has
integrated experience of previous trials into protocol development
[36]. The experience in stroke demonstrates what can be achieved
when clinical interest is backed by an international research
infrastructure. In order to achieve a high quality evidence base for
clinical treatment in TBI that is comparable to stroke, substantial,
high quality, relevant clinical trials are required.
This analysis examines the clinical research effort in TBI over
the last decade, and compares it with stroke. The analysis focuses
on key desirable study characteristics, and explores what lessons
the neurotrauma clinical research community could learn from
other clinical areas and new research paradigms.
Materials and Methods
This is an observational, cross-sectional study of all clinical
studies in TBI and stroke which were registered on the Clinical
Trials Database (www.clinicaltrails.gov) between January 2000
and January 2013, inclusive. This analysis was conducted and
reported according to the internationally agreed STrengthening
the Reporting of OBservational studies in Epidemiology
(STROBE) criteria [38]. The ClinicalTrials.gov database is the
largest study database, and was chosen because of its size, ease of
searching and capability to download data in a readily analysable
format. Previous studies have used this database successfully to
analyse study characteristics [39–42] and to compare study
characteristics in different diseases.
The ‘Advanced Search’ function was used with the following
terms ‘‘Stroke’’ and ‘‘Traumatic Brain Injury’’ with results being
time-limited to 01/01/2000 to 01/31/2013. All studies listed
under ‘‘Stroke’’ and ‘‘Cerebrovascular Disease’’ were also
downloaded to ensure all potentially relevant stroke studies were
obtained. In order to account for the very wide range of
classifications for TBI, all studies listed under the following Topic
categories were also downloaded: ‘‘Craniocerebral Injury’’,
‘‘Chronic Brain Injury’’, ‘‘Brain Hemorrhage, traumatic’’, ‘‘Cere-
bral haemorrhage, traumatic’’, ‘‘Brain concussion’’, ‘‘Post-trau-
matic epilepsy’’ and ‘‘Brain Injuries’’. Study details were
downloaded as datasets and analysed in Microsoft Excel. All
studies were manually checked for duplicates and suitability for
inclusion. Studies were excluded if recruitment occurred outside of
the specified analysis period, if the pathology investigated was not
stroke or TBI (e.g. infantile ischaemia encephalopathy), or if the
study population included non-stroke and non-TBI neurological
disease (e.g. studies investigating intracranial hypertension as a
result of any acute brain injury).
The registered enrolment number was manually checked for all
studies whose registered status was ‘Completed’. The study title was
used as a search string in both PubMed and Google Scholar and any
publications found were used to verify actual enrolment numbers.
Approximately one-third of studies could be verified in this way.
Studies classified as ‘Interventional’ (ClinicalTrials.gov Catego-
ry: Study Types) were analysed further. This classification includes
all studies where an intervention of any type (including drugs,
procedures, rehabilitation strategies etc.) was investigated and
distinguishes these studies from purely observational studies.
Table 1 summarises how the studies were subsequently sub-
classified. The full database and online registration entry was
manually checked for any study which had missing information on
the downloaded summary.
Results
The initial search criteria revealed 3716 unique studies in stroke
and 1125 unique studies in TBI. We excluded 2156 stroke studies
and 722 TBI studies from further analysis. Descriptive data of the
enrolment for these studies are presented below and study
characteristics are presented for the 1168 stroke and 268 TBI
interventional studies found within the completed search (Figure 1).
Table 1. Categorisation of study characteristics.
Characteristic Registered label Categories for analysis
Study Designs Randomised, Non-Randomised Randomised, Non-Randomised
Age Groups Child Paediatric
Adult, Adult|Senior Adult
Child|Adult, Child|Adult|Senior Both
Interventions Categories were: ‘Drug’, ‘Device’, ‘Behaviour’,
‘Procedure’, ‘Other’ followed by a freetext description
Drug (includes blood products, intravenous fluid
preparations)
Device (includes non-invasive brain stimulation)
Cognitive/Behaviour therapies
Non-cognitive/behavioural therapies e.g.
physiotherapy, treadmill training
Procedure (includes surgical procedures)
Protocol (includes educational measures)
Severity (TBI studies only) n/a Manual checking in inclusion criteria
Phases (only analysed for drug studies) 0, 1, 2, 3, 4, more than one phase noted 0, 1, 2, 3, 4, mixed phase
Location (manual checking of each
study webpage)
n/a Single Centre
Multi-centre (same country)
International
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The relative number of clinical studies in TBI does not
reflect its relative public health impact
The research effort in stroke is substantially greater than TBI, as
measured by the total participant enrolment number (stroke
n= 1 953 349 vs TBI n= 456 517), the total number of studies
(stroke n= 1503 vs TBI n= 402) and the number of interventional
studies (stroke n= 1168 vs TBI n= 268) (Fig. 2).
The growth of TBI research lags behind the growth in
stroke research
The number of studies starting recruitment per year has
increased over the last 12 years for both stroke and TBI. However,
there has been a much slower growth rate for TBI studies, with an
average of 14 new studies per year in stroke, compared with only 5
new studies per year for TBI (Fig. 3).
Studies with small recruitment numbers form the
majority of both stroke and TBI studies
The majority of studies in both stroke and TBI have small
recruitment numbers. Overall, 84% of stroke studies and 94% of
TBI studies have a projected or actual recruitment of fewer than
1000 participants, with a median (interquartile range) or subject
numbers of 100 (36–328) and 90 (34–180) respectively. Forty-
seven percent of stroke studies and 53% of TBI studies recruit
fewer than 100 participants (Fig. 4). These findings are consistent
with those previously reported for studies within this database
[39].
The majority of stroke and TBI studies are interventional
studies
Interventional studies make up 77% (n= 1168) and 66%
(n= 268) of total stroke and TBI studies registered on this
database respectively. Sixty percent (n = 1 168 311) [95% CI: 62–
58%] of participants in stroke studies and 79% (n= 359 482) [95%
CI: 75–82%] in TBI studies are enrolled in interventional studies.
Randomised control trials make up the vast majority of both
interventional TBI (81% n=958) and stroke (82% n=217)
studies.
The largest group of interventional studies are drug studies for
both stroke (44%) and TBI (57%) (Table 2). TBI has a much
higher proportion of cognitive/psychological therapies (stroke
2.3% vs TBI 19.5%).
For drug trials, Trial Phase information was only available in
69% (n= 801) of stroke studies and in 65% (n= 185) of TBI
studies. Of those studies in which Trial Phase information was
available, stroke research had 13 Phase 0, 99 Phase I, 215 Phase
II, 215 Phase III, 143 Phase IV and 115 mixed phase trials
whereas TBI research had 2 Phase 0, 24 Phase I, 50 Phase II, 41
Phase III, 42 Phase IV and 26 mixed phase trials.
Single-centre studies dominate in both TBI and stroke
research
The majority of interventional studies for both stroke and TBI
recruit from single centres with international studies representing
both a minority of studies (stroke n= 164 vs TBI n=15) and
participants (stroke n= 565 320 [48%, 95% CI: 45–51%] vs
TBI= 5105 [1.4%, 95% CI: 0–3%]). However, stroke has a much
higher percentage of international studies (stroke 15% [95% CI:
13%–17% vs TBI 6% [95% CI: 3%–9%]) (Figure 5).
Interventional studies in TBI recruit across all age groups
and severity types
TBI studies have a higher proportion which investigate children
(4% [n=12] exclusively recruiting children and 23% [n= 62]
recruiting both children and adults) as compared with stroke
studies (1% [11] exclusively recruiting children and 8% recruiting
all ages [82]).
The majority of interventional TBI studies recruit moderate-
severe TBI patients (87.3%, n= 234). Forty-one percent (n = 111)
of interventional TBI studies recruit only moderate/severe TBI
patients. Thirty-seven percent (n = 100) also recruited mild TBI
patients but all recruited patients had evidence of deficit, for
example, impaired performance in cognitive assessments. A fifth of
studies (20.5%, n= 55) recruited mild TBI patients but did not
specify whether a specific deficit needed to be present.
Figure 1. Flowchart of study inclusion for and exclusion from
analysis for a) stroke studies and b) TBI studies.
doi:10.1371/journal.pone.0084336.g001
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Figure 2. Key characteristics of TBI epidemiology and research as compared to stroke. The data for TBI are presented as a ratio of the
stroke data. TBI has a similar prevalence and higher incidence when compared to stroke, but total recruitment numbers and number of studies are
significantly fewer than in stroke.
doi:10.1371/journal.pone.0084336.g002
Figure 3. Number of studies starting recruitment in each year for stroke and TBI. Stroke has a greater increase in the number of studies
starting recruitment annually as compared to TBI.
doi:10.1371/journal.pone.0084336.g003
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Discussion
This study investigated quantitatively the clinical studies
registered on the ClinicalTrials.gov database in the fields of stroke
and TBI with regard to study characteristics.
We compared in particular the following characteristics
between TBI and stroke clinical research: recruitment number,
study count, and trends in annual study registration. These
parameters greatly influence the likelihood of practice changing
results from clinical trial efforts.
Overall, the research effort in stroke, as measured by number of
studies and patient recruitment, is significantly greater that in TBI.
This discrepancy is in contrast to the comparative public health
impact of these two diseases as measured by incidence, prevalence,
and cost [3,4]. This mismatch is particularly stark when compared
to the research profile within other specialties. For example, a
recent review of oncological clinical trials registered in Clinical-
Trials.gov demonstrated a positive correlation between number of
trials conducted into each cancer type and its associated public
health impact (incidence and mortality) [42].
The majority of clinical trials in both stroke and TBI were drug
trials. Although surgical interventions have been trialled and are
now commonly used in ischaemic stroke [43], such interventions
are much more commonly used, and should hence be trialled, in
TBI. Given the absence of a clear commercial motivation, trials of
surgical intervention are mostly funded by public grants. In most
cases, surgical therapies will evaluate the relative merit of one
existing intervention over another in an attempt to provide an
evidence base for current surgical practice. An additional
difference for trials of surgical intervention is that they are not
driven by the stringent and restrictive regulatory framework which
exists for trials of new medicinal products [44]. Development of a
new drug, on the other hand, requires substantial financial
investment prior to phase III trials. Given the long list of negative
clinical trials of presumed neuroprotective agents, there is now
considerable reluctance amongst companies to proceed along this
path. As a result, most TBI drug trials currently investigate new
licensing indications for already available drugs and do so with
public funding.
Level 1 evidence can only be obtained from sufficiently powered
randomised controlled trials (RCTs). Multi-centre and multi-
ethnicity recruitment also results in better generalizability of
results. An encouraging finding is that the majority of clinical trials
in both stroke and TBI are RCTs. However, only 6% of trials in
TBI recruit internationally compared to 15% in stroke. In
addition, while the last decade has seen a rise in clinical trial
activity for both conditions, the rate of increase is higher for stroke
and the absolute difference in trial activity between stroke and TBI
is consequently larger each year.
For both conditions, stroke and TBI, the majority of studies are
small (around half recruit fewer than 100 patients) and the
overwhelming majority of both stroke and TBI studies recruit
fewer than 1000 patients. The small recruitment numbers may
Figure 4. Number of studies per enrolment interval. The vast majority of both stroke (84%) and TBI (94%) studies recruit fewer than 1000
participants. NK= not known.
doi:10.1371/journal.pone.0084336.g004
Table 2. Number of interventional studies investigating each
type of intervention.
Intervention Stroke TBI
Drug 512 151
Device 273 20
Cognitive/Behavioural 27 52
Non cognitive/behavioural therapies 230 12
Procedure 58 16
Protocol 51 13
Mixed 17 4
doi:10.1371/journal.pone.0084336.t002
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partly be due to the desire to recruit as homogenous a study
population as possible. However, it is likely that many of the
smaller studies will be under-powered. The implications of this are
both clinical (since the results will not be informative for clinical
practice) and scientific (since under-powered studies overestimate
effect size, which will negatively influence the planning of further
studies) [45]. Additionally, a large number of small trials will
reduce the number of patients that consent to large, multi-centre
trials and this will further hinder the development of successful
interventions.
Recruitment is a particular difficulty for TBI studies, and this is
likely to be an important reason for the abundance of small-scale
studies. Some of this is attributable to the ethics of recruiting TBI
patients in the acute period where they are unable to consent.
Research without consent is not a readily accepted idea [46] but
TBI clinical trials have protocols to enable recruitment, for
example, consent from family members with renewal of consent
from patients if they later regain capacity. However, by far the
biggest reason for recruitment difficulties is due to the pathological
and clinical heterogeneity of the TBI population. For example, the
DECRA trial screened 3478 severe TBI patients but excluded only
21 for consent issues [47,48]. The large majority were excluded
because the TBI did not have the characteristics needed for the
trial. On the other hand, a recent drug trial of minor stroke/
transient ischaemic attacks excluded patients primarily for
protocol reasons, for example, delayed presentation [48]. The
heterogeneity of TBI disadvantages TBI research in the traditional
clinical trial format,
Therefore, the research effort into TBI not only needs to
increase in quantity, but also needs to alter its approach.
Adaptations to the traditional RCT design, in particular Com-
parative Effectivness Research (CER) and Multi-Arm Multi-Stage
(MAMS) studies, may be particularly useful in TBI [49,50].
A key concept of CER is that of Pragmatic trials, where the
effectiveness of an intervention is evaluated for real-world patient
populations and healthcare conditions [49]. This would enable
broader applicability of results. Another aspect of CER is the
combination of many data sources, observational as well as
interventional studies; this could enable the results of smaller-scale
studies to be combined in meta-analyses that are more likely to
yield practice-changing conclusions. One other important concept
of CER is that of sub-population analysis; this would increase
recruitment as the inclusion criteria could be broader and, if
appropriately powered, heterogeneities in the trial population are
turned into an advantage.
A MAMS trial uses a single control group with several parallel
intervention arms (the ‘multiple arms’). This saves on the number
of patients required since only one control group is required.
Interim analyses are performed to identify interventions which are
likely to be ineffective; these are terminated early and, where
possible, the participants in these arms crossover into the ongoing
intervention arms (the ‘multiple stages’). This increases the
recruitment number in each of the final interventions which
increases the trial’s power [50]. MAMS design has been
successfully adopted in cancer trials [50–52]. However, both
MAMS and CER designs would help to maximise the efficiency of
recruitment as each enrolled participant has a higher chance of
receiving an effective intervention and, as a consequence, the
resulting studies have greater power. Encouraging collaboration
through international research networks along with consensus
statements among clinicians on efforts in TBI trials are crucial
factors for enabling CER and MAMS trials. Strengthening such
networks will additionally improve the capacity for performing
large-scale, multi-centre trials.
As well as trial design, there are other relevant issues when
considering the future of TBI research. TBI is traditionally
classified according to severity. Severe TBI, though representing
the minority (,10%) of total TBI [53], has the highest associated
relative mortality and morbidity, so it is unsurprising that the
majority of TBI studies recruit severe TBI. However, we included
all TBI studies in our comparison because there is a growing
realisation that ‘mild’ TBI, even those not initially requiring
medical attention, can result in long-term neuropsychological
consequences. The American Academy of Neurology has recently
published a consensus statement on managing concussion at the
sidelines of contact sport games, with the view that these impacts
can result in long-term damage [54]. Veterans of the Iraq/Afghan
wars sustaining blast injuries, which had been classified as ‘mild’
TBIs, can have long-term cognitive deficits [55]. People in
professions exposing them to mild head injuries also appear to
Figure 5. Figure depicts location of study recruitment. The majority of both stroke (58%) and TBI (67%) studies are single centre. NK =not
known.
doi:10.1371/journal.pone.0084336.g005
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sustain cognitive consequences along with biological evidence of
neuronal damage [56]. Therefore, given that even a mild ‘TBI’
can lead to cognitive consequences, and that cognitive conse-
quences are a major influence on outcome [57], the study of mild
TBI is an important future area of research.
Attention to the finer details of methodology is also important to
improve the quality of TBI trials. It is particularly crucial to use
appropriate outcome measures when designing trials which will
impact clinical practice. The outcomes recorded in trials must be
important to patients e.g. return to work, level of independence, as
well as healthcare providers e.g. mortality, use of healthcare
resources. This is a particular challenge for TBI trials for several
reasons. First, heterogeneity in pre-morbid characteristics and
mechanism and extent of injury produces a vast number of
different deficits. These range from physical signs e.g. limb
weakness to physical symptoms e.g. headaches and dizziness, from
cognitive e.g. concentration and attentional difficulties to neuro-
psychiatric e.g. irritability. Second, ‘secondary deficits’ can also
occur and have a significant impact on recovery e.g. seizures can
result in reduced independence through loss of the ability to drive.
Third, the common methods of synthesising the impact of these
many heterogenous deficits have problems of their own. Outcome
‘batteries’ and combined scoring systems often have no particular
logic reported for the relative weighting of each component.
Generic quality of life scores e.g. GOS/GOS-E, SF-36, QUOLI-
BRI-TBI all have their own biases. Fourth, many of the outcome
measures important to patients (e.g. return to work/education),
whilst pragmatic, are very insensitive due to their myriad
components. For example, an intervention to improve concentra-
tion may be very effective but the patient is still unable to return to
their previous work as a bus driver because they have seizures.
Thus, within the confines of available outcomes measures,
appropriate selection and powering is crucial. Fifth, patients’
self-evaluation of their recovery may not truly reflect their
recovery e.g. due to loss of insight, due to depression [58]. In
these situations, carer evaluation may be helpful [59].
The success of clinical trials in TBI is, of course, dependent on
the validity of the underlying hypothesis for the intervention. New
trials, therefore, must be based on pre-clinically tested and verified
interventions. Assumptions, particularly from pre-clinical drug
studies on animal models, should be critically evaluated for their
applicability to ‘real life’ TBI before they are allowed to influence
study design [34].
A final point to consider is that of funding. Stroke and TBI both
result in significant burdens to the individual and society. To put
this into context, cancer, of any type, has an annual incidence of
approximately 320 000 in the UK, as compared with 150 000 for
stroke and 135 000 for TBI requiring hospital admission [60–63].
In 2012, the main charities for specialty research funding in the
UK spent £332 million on cancer research, compared with £4
million for stroke and less than £100 000 for TBI research [63–
65] (charity annual accounts). Whilst charitable funding for TBI
research also comes from other sources in the UK, it is unlikely to
amount to more than £10million per annum. This means that
TBI receives disproportionately little funding. This will impact on
the type of trials which can be performed since high-quality, multi-
centre, large-scale trials require substantial funding.
Limitations
There are two main limitations of our study.
First, we used a single database. Not all clinical trials may be
registered on ClinicalTrials.gov [66], and the widening of this
analysis to other databases, for example the World Health
Organisation portal, would provide more security that the analysis
was complete. This may be a particular issue for small scale
observational studies, since there are no regulatory or publication
requirements to register these. Thus, the number of observational
studies found on the ClnicalTrials.gov database may well be an
underestimate. However, the second part of our analysis relies on
interventional studies, where the registration bias may be less
relevant. Analysis of the chosen database has been employed by
previous studies and there is consensus that the ClinicalTrials.gov
database includes a representative majority of clinical trials [39–
42].
Second, entry of information into this database is by investiga-
tors of sponsors from the trial team and our analyses inevitably
depends on the quality of data recorded. Although there are
automated and manual procedures in place to improve the
accuracy and relevance of the information available (e.g.
reminders to the researchers), there is no mandated requirement
to update entries [67]. We attempted to minimise some of these
issues by manually checking some fields e.g. enrolment numbers.
Third, a direct comparison between TBI and stroke clinical trial
research is limited by the significant variability within TBI
severuty, which does not characterise stroke to the same extent.
Many cases of ‘mild’ TBI, unless they occur within a specified
setting, such as contact sports, do not receive specialist medical
attention. On the other hand, most ‘minor’ stroke/transient
ischaemic attack patients will receive prompt specialist medical
attention. Thus, there is likely to be a selection bias against ‘mild’
TBI research which limits the usefulness of a direct TBI and stroke
research database comparison. This bias can be expected to
improve with growing clinical recognition of ‘mild’ TBI and with
new study designs which can adequately analyse the entire
spectrum of TBI disease.
Conclusions
Analysis of the trials registered on the ClinicalTrials.gov
database demonstrates substantial differences between the re-
search effort into stroke and TBI. This is even more concerning
when considering the gap in the context of other disease burdens.
This gap is in sharp contrast to the equivalent public health
importance of the two diseases. Furthermore, trial registration
statistics of recent years indicate that this imbalance is likely to
worsen further in favour of stroke in the years to come. However,
it is not simply enough to increase the number of studies, if their
design does not allow them to actually answer important questions.
Instead, TBI translational research must learn from other diseases
and specialties, such as stroke, cardiovascular disease, and
oncology, where major clinical advances have been made through
large-scale, multi-centre trials studying interventions based robust
preclinical data and hypotheses. Collaborative efforts within the
research community, improved funding structures and thinking
beyond the traditional clinical trial format will improve both the
quantity and quality of clinical trial research into TBI.
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